EVRRF (Molecule Holdings) Operating Income: $-1.93 Mil (TTM As of Jul. 2023)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

What is Molecule Holdings Operating Income?

Molecule Holdings EVRRF -99.96% Operating Income is $-1.93 Mil as of Jul. 2023.

Molecule Holdings's Operating Income for the three months ended in Jul. 2023 was $-0.24 Mil. Its Operating Income for the trailing twelve months (TTM) ended in Jul. 2023 was $-1.93 Mil.

Operating Margin % is calculated as Operating Income divided by its Revenue. Molecule Holdings's Operating Income for the three months ended in Jul. 2023 was $-0.24 Mil. Molecule Holdings's Revenue for the three months ended in Jul. 2023 was $0.54 Mil. Therefore, Molecule Holdings's Operating Margin % for the quarter that ended in Jul. 2023 was -43.89%.

Molecule Holdings's 5-Year average Growth Rate for Operating Margin % was 0.00% per year.

Operating Income or EBIT is linked to Return on Capital for both regular definition and Joel Greenblatt's definition. Molecule Holdings's annualized ROC % for the quarter that ended in Jul. 2023 was -15.86%. Molecule Holdings's annualized ROC (Joel Greenblatt) % for the quarter that ended in Jul. 2023 was -71.44%.


Molecule Holdings  (OTCPK:EVRRF) Operating Income Explanation

1. Operating Income or EBIT is linked to Return on Capital for both regular definition and Joel Greenblatt's definition.

Molecule Holdings's annualized ROC % for the quarter that ended in Jul. 2023 is calculated as:

ROC % (Q: Jul. 2023 )
=NOPAT/Average Invested Capital
=Operating Income * ( 1 - Tax Rate % )/( (Invested Capital (Q: Apr. 2023 ) + Invested Capital (Q: Jul. 2023 ))/ count )
=-0.948 * ( 1 - 0% )/( (5.925 + 6.033)/ 2 )
=-0.948/5.979
=-15.86 %

where

Note: The Operating Income data used here is four times the quarterly (Jul. 2023) data.

2. Joel Greenblatt's definition of Return on Capital:

Molecule Holdings's annualized ROC (Joel Greenblatt) % for the quarter that ended in Jul. 2023 is calculated as:

ROC (Joel Greenblatt) %(Q: Jul. 2023 )
=EBIT/Average of (Net fixed Assets + Net Working Capital)
=EBIT/Average of (Property, Plant and Equipment+Net Working Capital)
     Q: Apr. 2023  Q: Jul. 2023
=EBIT/( ( (Property, Plant and Equipment + Net Working Capital) + (Property, Plant and Equipment + Net Working Capital) )/ count )
=-1.188/( ( (1.707 + max(-1.317, 0)) + (1.619 + max(-1.526, 0)) )/ 2 )
=-1.188/( ( 1.707 + 1.619 )/ 2 )
=-1.188/1.663
=-71.44 %

where Working Capital is:

Working Capital(Q: Apr. 2023 )
=(Accounts Receivable + Total Inventories + Other Current Assets) - (Accounts Payable & Accrued Expense + Defer. Rev. + Other Current Liabilities)
=(0 + 0.504 + 0.129) - (1.95 + 0 + 0)
=-1.317

Working Capital(Q: Jul. 2023 )
=(Accounts Receivable + Total Inventories + Other Current Assets) - (Accounts Payable & Accrued Expense + Defer. Rev. + Other Current Liabilities)
=(0.265 + 0.242 + 0.154) - (2.188 + 0 + -0.00099999999999945)
=-1.526

When net working capital is negative, 0 is used.

Note: The EBIT data used here is four times the quarterly (Jul. 2023) EBIT data.

3. Operating Income is also linked to Operating Margin %:

Molecule Holdings's Operating Margin % for the quarter that ended in Jul. 2023 is calculated as:

Operating Margin %=Operating Income (Q: Jul. 2023 )/Revenue (Q: Jul. 2023 )
=-0.237/0.54
=-43.89 %

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

4. Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the Operating Income growth rate using Operating Income per share data.


Be Aware

Compared with a company's EBITDA margin, Operating Margin can be manipulated by adjusting the rate of depreciation, depletion and amortization (DDA).

If a company is facing competition, its Operating Margin may decline. Often the Operating Margin declines well before the company's revenue or even profit decline. Therefore, Operating Margin is a very important indicator of whether the company is facing problems.

For instance, by 2012, Nokia (NOK)'s problems were well known and its stock had lost more than 90% of its market value since 2007. But Nokia's Operating Margin had already been in decline since 2002, although its earnings per share were still rising. Investors who paid attention to Operating Margin would have avoided this huge loss. The same can be said for Research-in-Motion (RIMM).

Therefore, Operating Margin is a very important screening filter for GuruFocus. GuruFocus's Buffett-Munger screener requires that the profit margin is either consistent or expanding. The Model Portfolio of the Buffett-Munger screener has outperformed the market every year since inception in 2009.


Molecule Holdings Operating Income Related Terms


Molecule Holdings Operating Income Historical Data

* Premium members only.

The historical data trend for Molecule Holdings's Operating Income can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Molecule Holdings Operating Income Chart

Molecule Holdings Annual Data
Trend Oct19 Oct20 Oct21 Oct22
Operating Income
-0.83 -1.38 -2.73 -2.86

Molecule Holdings Quarterly Data
Jul19 Oct19 Jan20 Apr20 Jul20 Oct20 Jan21 Apr21 Jul21 Oct21 Jan22 Apr22 Jul22 Oct22 Jan23 Apr23 Jul23
Operating Income Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only -0.58 -0.91 -0.57 -0.23 -0.24

Molecule Holdings Operating Income Calculation

Operating Income, is the profit a company earned through operations. All expenses, including cash expenses such as cost of goods sold (COGS), research & development, wages, and non-cash expenses, such as depreciation, depletion and amortization, have been deducted from the sales.

Operating Income for the trailing twelve months (TTM) ended in Jul. 2023 adds up the quarterly data reported by the company within the most recent 12 months, which was $-1.93 Mil.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Frequently Asked Questions Learn more about Operating Income →
What does a Operating Income of $-1.93 Mil mean?
Molecule Holdings (EVRRF) has a Operating Income of $-1.93 Mil as of Jul. 2023. Operating Income equals sales less all operating expenses. It is linked to EBIT. View historical data on Molecule Holdings and its competitors.
Is Molecule Holdings' Operating Income too high?
Molecule Holdings' current Operating Income is $-1.93 Mil.
How does Molecule Holdings' Operating Income compare to ZTS?
Molecule Holdings' Operating Income of $-1.93 Mil can be compared against companies in the Drug Manufacturers industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Operating Income for a Drug Manufacturers company?
A good Operating Income depends on the Drug Manufacturers industry context. However, Operating Income should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Operating Income mean?
A high Operating Income can signal that a stock is expensive relative to its fundamentals. Operating Income equals sales less all operating expenses. It is linked to EBIT. View historical data on Molecule Holdings and its competitors. Molecule Holdings's current Operating Income is $-1.93 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Molecule Holdings stock overvalued right now?
Molecule Holdings (EVRRF) has a current Operating Income of $-1.93 Mil. The current Operating Income is $-1.93 Mil. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Operating Income calculated?
Operating Income is calculated from a company's financial statements. For Molecule Holdings (EVRRF), the current Operating Income is $-1.93 Mil as of Jul. 2023. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Molecule Holdings Business Description

Address 591 Reynolds Road, Landsdowne, ON, CAN, K0E 1L0
Molecule Holdings Inc is a licensed cannabis beverage company. It is engaged in the production, packaging, and distribution of beverages related to cannabis.